Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes

Cardiovascular diseases and diabetes mellitus are currently among the diseases with the highest morbidity and mortality. The pathogenesis and development of these diseases remain strongly connected, along with inflammation playing a major role. Therefore, the treatment possibilities showing a positive impact on both of these diseases could be especially beneficial for patients. SGLT-2 inhibitors and GLP-1 receptor agonists present this dual effect. Moreover, the hostile composition of the gut microbiota could influence the progression of these conditions. In this review, the authors present the latest knowledge on and innovations in diabetes mellitus and CVD-with the focus on the molecular mechanisms and the role of the microbiota.

Automated summary

Cardiovascular diseases and diabetes mellitus have high morbidity and mortality rates, and they are closely linked with inflammation playing a significant role. SGLT-2 inhibitors and GLP-1 receptor agonists have a positive impact on both diseases. Furthermore, the composition of the gut microbiota can affect the progression of these conditions.